184 related articles for article (PubMed ID: 2914544)
1. Refractory duodenal ulcers (nonhealing duodenal ulcers with standard doses of antisecretory medication).
Collen MJ; Stanczak VJ; Ciarleglio CA
Dig Dis Sci; 1989 Feb; 34(2):233-7. PubMed ID: 2914544
[TBL] [Abstract][Full Text] [Related]
2. Bleeding duodenal ulcer. Role of gastric acid hypersecretion.
Collen MJ; Kalloo AN; Sheridan MJ
Dig Dis Sci; 1993 Feb; 38(2):269-75. PubMed ID: 8093870
[TBL] [Abstract][Full Text] [Related]
3. Gastric ulcers differ from duodenal ulcers. Evaluation of basal acid output.
Collen MJ; Sheridan MJ
Dig Dis Sci; 1993 Dec; 38(12):2281-6. PubMed ID: 8261834
[TBL] [Abstract][Full Text] [Related]
4. Definition for idiopathic gastric acid hypersecretion. A statistical and functional evaluation.
Collen MJ; Sheridan MJ
Dig Dis Sci; 1991 Oct; 36(10):1371-6. PubMed ID: 1914757
[TBL] [Abstract][Full Text] [Related]
5. Famotidine in the treatment of duodenal ulcers resistant to other histamine H2-receptor antagonists.
Chen PH; Wang TH; Wang CY; Chen CY; Cheng TC; Tsai YT; Siauw CP; Yang KC; Chen GH; Sung JL
J Int Med Res; 1989; 17 Suppl 1():25A-31A. PubMed ID: 2566541
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for delayed healing of duodenal ulcers treated with famotidine and ranitidine.
Reynolds JC; Schoen RE; Maislin G; Zangari GG
Am J Gastroenterol; 1994 Apr; 89(4):571-80. PubMed ID: 8147361
[TBL] [Abstract][Full Text] [Related]
7. Idiopathic gastric acid hypersecretion: treatment implications for refractory acid/peptic disorders.
Lewis JH
Aliment Pharmacol Ther; 1991; 5 Suppl 1():15-24. PubMed ID: 1888834
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the effects of gastric antisecretory agents in healthy volunteers and patients with duodenal ulcer.
Howden CW; Jones DB; Burget DW; Hunt RH
Gut; 1986 Sep; 27(9):1058-61. PubMed ID: 3758819
[TBL] [Abstract][Full Text] [Related]
9. A multicenter, randomized, double-blind study comparing a daily bedtime administration of famotidine and ranitidine in short-term treatment of active duodenal ulcer.
Alcalá-Santaella R; Guardia J; Pajares J; Piqué J; Pita L; Alvárez E; Castellanos P; Guarner L; Ortiz J; Pesquera R
Digestion; 1989; 42(2):79-85. PubMed ID: 2670647
[TBL] [Abstract][Full Text] [Related]
10. A multicenter, randomized, double-blind study comparing once-daily bedtime administration of famotidine and ranitidine in the short-term treatment of active duodenal ulcer.
Alcalá Santaella R; Guardia J; Pajares J; Pique J; Pita L; Alvárez E; Castellanos P; Guarner L; Ortiz J; Pesquera R
Hepatogastroenterology; 1989 Jun; 36(3):168-71. PubMed ID: 2666293
[TBL] [Abstract][Full Text] [Related]
11. Continuous 24-hour intragastric pH monitoring in the evaluation of the effect of a nightly dose of famotidine, ranitidine and placebo on gastric acidity of patients with duodenal ulcer.
Savarino V; Mela GS; Scalabrini P; Di Timoteo E; Magnolia MR; Celle G
Digestion; 1987; 37(2):103-9. PubMed ID: 3305114
[TBL] [Abstract][Full Text] [Related]
12. Effects of 800 mg cimetidine once daily on gastric acid secretion.
Dammann HG; Walter TA; Mueller P; Simon B
Scand J Gastroenterol Suppl; 1986; 121():25-9. PubMed ID: 3532295
[TBL] [Abstract][Full Text] [Related]
13. Giant duodenal ulcer. Evaluation of basal acid output, nonsteroidal antiinflammatory drug use, and ulcer complications.
Collen MJ; Santoro MJ; Chen YK
Dig Dis Sci; 1994 May; 39(5):1113-6. PubMed ID: 8174425
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and tolerability of famotidine and ranitidine on the healing of active duodenal ulcer and during six-month maintenance treatment, with special reference to NSAID/aspirin-related ulcers.
Bank S; Greenberg RE; Magier D; Lavin PT
Clin Ther; 1991; 13(2):304-18. PubMed ID: 1863945
[TBL] [Abstract][Full Text] [Related]
15. A multicenter, randomized, double-blind study comparing famotidine with ranitidine in the treatment of active duodenal ulcer disease.
McCullough AJ
Am J Med; 1986 Oct; 81(4B):17-24. PubMed ID: 2877570
[TBL] [Abstract][Full Text] [Related]
16. Ranitidine in the treatment of duodenal ulcer disease: relationship between antisecretory effect and ulcer healing rate.
McIsaac RL; Dixon JS; Mills JG; Wood JR
Aliment Pharmacol Ther; 1991 Jun; 5(3):227-43. PubMed ID: 1888823
[TBL] [Abstract][Full Text] [Related]
17. Comparison of famotidine with cimetidine and ranitidine.
Berardi RR; Tankanow RM; Nostrant TT
Clin Pharm; 1988 Apr; 7(4):271-84. PubMed ID: 2896559
[TBL] [Abstract][Full Text] [Related]
18. Changes in nocturnal and peak acid outputs after duodenal ulcer healing with sucralfate or ranitidine.
Kummer AF; Johnston DA; Marks IN; Young GO; Tigler-Wybrandi NA; Bridger SA
Gut; 1992 Feb; 33(2):175-8. PubMed ID: 1541412
[TBL] [Abstract][Full Text] [Related]
19. Morning versus evening dose: a comparison of three H2-receptor blockers in duodenal ulcer healing.
Khasawneh SM; Affarah HB
Am J Gastroenterol; 1992 Sep; 87(9):1180-2. PubMed ID: 1519576
[TBL] [Abstract][Full Text] [Related]
20. [Famotidine versus ranitidine in the acute treatment of duodenal ulcer. A multicenter comparative study in Germany].
Simon B; Dammann HG; Jakob G; Miederer SE; Müller P; Ottenjann R; Paul F; Scholten T; Schütz E; Seifert E
Z Gastroenterol; 1985 Feb; 23(2):47-51. PubMed ID: 2865859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
